

Identifying heterogeneous treatment effects of the COVID-19 pandemic on non-fatal opioid overdose among New York State Medicaid enrollees

John R. Pamplin II, PhD, MPH
World Congress of Epidemiology 2024

September 27, 2024




Figure 1a. 12 Month-ending Provisional Counts of Drug Overdose Deaths: United States



Advocacy Resource Center


Advocating on behalf of physicians and patients at the state level

Issue brief: Reports of increases in opioid- and other drug-related overdose and other concerns during COVID pandemic



KFF Opioid Overdose Deaths by Race/Ethnicity | KFF

Timeframe: 2018 - 2022



Objective


Identify subpopulations of the New York state Medicaid population who experienced the greatest increases in risk of non-fatal opioid overdose following onset of the COVID-19 pandemic

Data

Center for Medicare and Medicaid Services COVID-19 Supplement

- Cohort of NYS Medicaid beneficiaries (n = 1,235,335)
 - Aged 18-64
 - Continuously enrolled for 10-months as of February 2020
- Outcome defined as non-fatal opioid overdose
 - ICD-10 codes: X40-X44, X60-X64, X85, Y10-Y14, T40.0-T40.4
 - Observation period begins March 1, 2019

Study Timeline



* “Treatment” = Emergence of the COVID-19 Pandemic in NYS

Predictors

- **Individual-level**
 - Age, race/ethnicity, gender, disability status, chronic pain, opioid use disorder (OUD), treatment for OUD, Health Service Area
 - Assessed at beginning of observation period
- **Contextual-level (census tract-linked ACS data)**
 - Population density, median household income, gender, age, race/ethnicity, marital status, employment, poverty, home ownership, housing stability, family size
 - Operationalized in quintiles

	<i>N</i> = 1,021,889		
	<i>N</i>	%	
Non-fatal overdose			
≥ 1 during Pre-COVID	1871	0.18%	
Aged, Blind, Disabled	123457	12.08%	
Health Service Area			
Central NY	57103	5.59%	
Finger Lakes	54166	5.30%	
Mid-Hudson	79624	7.79%	
Nassau-Suffolk	81662	7.99%	
New York City	625401	61.20%	
Northeastern NY	47047	4.60%	
NY-Penn	9363	0.92%	
Western NY	67523	6.61%	
Baseline Documentation of Opioid Use Disorder	24592	2.41%	
Baseline Documentation of Opioid Use Treatment	11479	1.12%	
	45-54	238301	23.32%
	55-64	239225	23.41%

Edward McFowland III
Information and Decision Sciences,
Carlson School of Management,
University of Minnesota

Sriram Somanchi
IT, Analytics, and Operations,
Mendoza College of Business,
University of Notre Dame

Daniel B. Neill
Event and Pattern Detection Laboratory,
H.J. Heinz III College,
Carnegie Mellon University

Heterogeneous Treatment Effect Scan

- Identifies subgroups for whom the observed treatment effect is the most significantly different than the average effect of treatment under the null hypothesis
 - H_0 : uniform effect of treatment for all individuals
- Iteratively scans data for the subgroup with the greatest penalized log-likelihood statistic
 - $F(S) = \log(\Pr(\text{Data} \mid H_1(S)) / \Pr(\text{Data} \mid H_0))$
- Ran 100 iterations of HTE-scan
 - Permutation tested across 100 simulated datasets to assess statistical significance at $\alpha = .05$

Results

Subgroup 1: Older working-aged Black and Hispanic men

Black and Hispanic; male; aged 45-64; no history of OUD

N = 53,065

Penalized Log-likelihood score: 44.15

RR = 1.55


Subgroup 2: Older working-aged adults with Aged/Blind/Disabled status

Aged/Blind/Disabled status; aged 45-64; no history of OUD

N = 73,694

Penalized log-likelihood score: 41.46

RR = 1.57



Implications

- Prominent role of age, race/ethnicity, and disability status
 - Highlight role of structural factors in producing increased overdose risk
- Underlying mechanisms may be key targets for intervention during future Big Events
 - Further work to identify and study these mechanisms is vital
- Limitations
 - Limited generalizability (Medicaid enrollees; 18-64 years of age)
 - Could not look at fatal overdose due to inclusion criteria for parent study
 - Potential misclassification of outcome due to lack of formal diagnosis



Acknowledgments

NYU Center for Opioid Epidemiology & Policy:

- Magdalena Cerdá, DrPH, MPH
- Katherine Wheeler-Martin, MPH
- Allison Perry, MPH
- Noa Krawczyk, PhD

NYU CUSP Machine Learning for Good Laboratory

- Ravi Shroff, PhD, MS
- Daniel Neill, PhD, MPH

Rutgers University Center for Health Services Research

- Stephen Crystal, PhD

Columbia University Mailman School of Public Health

- Zachary Mannes, PhD
- Deborah Hasin, PhD
- Silvia Martins, PhD

Funding:

K01DA058085 (Pamplin)

R01DA045872-02S1 (Cerdá)

IIS-2040898 (Neill)



NYU

Center for Urban
Science + Progress

✉ jrp2166@columbia.edu

🐦 [@JohnPamplinI](https://twitter.com/JohnPamplinI)